VERIFIED AGAINST INDEPENDENT SOURCES
We check every story against its sources before publishing — and we show the work. How we verify →
The World Health Organization validated Chile as the first country in South America to eliminate dog-transmitted rabies to humans. The national achievement is based on a delivered public health result, not a projection. The last reported case of this type was in 1972.
The FDA approved Scholar Rock's drug Isembyld for US patients with spinal muscular atrophy aged 2 and older who are already on SMN2-targeting treatments. The drug is the first therapy to specifically target muscle loss in this condition. It is approved for use in combination with existing therapies, not as a standalone treatment, and its real-world effectiveness is not yet known.
The Australian Institute of Health and Welfare's National Drug Strategy Household Survey shows daily smoking rates dropped to 5.6% last year, down from 8.3% two years ago. This national figure comes from a single large survey and has not been independently corroborated by other sources.
The FDA has granted expedited approval to daraxonrasib, a first-of-a-kind pill that targets a mutated protein present in over 90% of pancreatic cancers. The approval is US-wide. However, the expedited status means its real-world effectiveness and broad patient access are not yet demonstrated.
Cambodia has become the first country in Asia to achieve a United Nations target for near-universal HIV diagnosis and treatment. The U.N. certified this national-level result. The specific U.N. target was not named in the provided information.
The FDA has approved Merck's first-in-class oral PCSK9 drug, Lipfendra, for high cholesterol on a national level. In six-month trials, the drug reduced LDL cholesterol by up to 60 percent. Its real-world impact is not yet known as the treatment is newly approved.
According to a Commonwealth Fund report covered by STAT, U.S. drug overdose deaths fell by 27% in 2024. Preliminary data for 2025 indicates the decline continued. The report notes that the reasons for this national decline are not yet fully understood.
A national service in England has dispensed nearly 305,000 free doses of the morning-after pill through pharmacies between October 2025 and March 2026. This figure covers the first six months of the scheme and is approximate.
The US FDA approved updated Covid-19 vaccines for the XFG variant. This is a national approval. Distribution has not yet started, and insurance coverage is still being determined.
The FDA has approved Isembyld, a new drug to treat muscle loss in patients with spinal muscular atrophy (SMA). The drug is approved as an add-on to existing therapies for the national, rare disease population of people aged 2 and older. The approval was based on clinical trial improvements in motor skills, and long-term real-world outcomes are not yet known.
The FDA has authorized an artificial intelligence algorithm called Queen of Hearts. The tool is designed to help clinicians identify harder-to-detect heart attacks from EKGs, a national authorization. The authorization was just issued, so the algorithm's impact in clinical practice is not yet proven.
The U.S. FDA has granted accelerated approval to Replimune's drug RP1 (Tudriqev) for advanced melanoma on a national level. The approval was based on a single trial for which FDA staff had expressed concerns. A confirmatory trial is ongoing, and the drug had been rejected twice previously.
The PRIMA retinal implant has been approved for use in Europe. It restores functional central vision in people with geographic atrophy, improving vision to roughly 20/160, which is not full restoration. The approval is based on a small study.
A genetically modified pig kidney worked for 271 days in a single patient, keeping him off dialysis as a bridge to a human transplant. The kidney ultimately failed due to infection and vascular damage. The procedure is considered an early-stage experiment.
The FDA approved Rasonque for national use. A clinical trial showed the drug nearly doubled overall survival. This benefit is based on a single study. Real-world effectiveness and long-term outcomes are not yet known.
The European Union has set a ban on BPA and other bisphenols in food packaging to take effect from July 2026, covering all 27 member states. The rules apply to food wrappers, containers, water bottles, lunch boxes and kitchenware. This is a forward-looking regulation, and any reduction in real-world BPA exposure has not yet been measured. The development comes from a single news report without independent corroboration provided here.
Researchers report that no women aged 20-24 in England died of cervical cancer between 2020 and 2024, which they describe as the first recorded five-year period with zero such deaths in this age cohort and attribute to high HPV vaccine uptake. The expected historical baseline is small, and this is an observational finding rather than a controlled causal demonstration. It has been reported by a single outlet citing a single research group, with no independent confirmation provided here.
A study found that London's ultra-low emission zone (Ulez) is linked to improved lung size and function in children. The research was conducted city-wide. The findings are from a single observational study, and the results may be influenced by other factors.
Rwandan authorities are conducting a nationwide crackdown on illegal alcohol. The enforcement action includes shutting down factories, seizing products, and recalling dozens of brands. The crackdown follows the deaths of 18 people in Bugesera from methanol-contaminated drinks. The enforcement is ongoing.
England and Wales have approved teplizumab for use on the NHS, making it available through the national health system to certain people at high risk of developing type 1 diabetes. The drug delays the onset of the disease by up to three years. It applies to a subset of at-risk individuals, not people already living with diabetes, and real-world rollout details and patient numbers have not yet been confirmed.
Lenacapavir is a drug administered by injection every six months, and its distribution is now starting. The rollout is global but targeted to areas with the greatest need. The effort is in its early stages, and there are concerns about equitable access.
The FDA approved Merck's Lipfendra nationwide for high-risk patients already taking statins. It is the first oral PCSK9 inhibitor. The approval is based on two studies and long-term data is limited to one year. Patients must take the medication on an empty stomach.
In March 2021, Berkeley became the first city to prohibit the display of sugary beverages and snacks in checkout lanes. The policy applies to stores within the city. This item reports on the implementation of the ban, not on the results of a study evaluating its effects.
The FDA has approved enlicitide, sold as Lipfendra, as the first oral PCSK9 inhibitor for lowering blood cholesterol. The national approval gives patients a pill option in a drug class previously available only by injection. Its real-world impact will depend on insurance coverage and physician adoption, and actual effectiveness and adherence outside trials remain to be seen.
The US Food and Drug Administration approved Takeda's drug Orzeyful for the treatment of narcolepsy type 1. This is a national approval for a rare disease. The drug is an orexin receptor agonist.